ORMP, US68403P2039

Oramed Pharmaceuticals schedules November 12 results for Oramed Pharmaceuticals stock

Published on 10/15/2026 at 20:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oramed's P/E was 1.01 on October 15, 2026. Oramed Pharmaceuticals stock was EUR 3.72 on October 15, 2026, unchanged versus Tradegate close.

Results date and valuation

Oramed Pharmaceuticals lists November 12, 2026 as its next quarterly reporting date.
Oramed's P/E ratio was 1.01 on October 15, 2026.
Oramed Pharmaceuticals stock costs EUR 3.72 at Lang & Schwarz on October 15, 2026 at 8:47 p.m. CEST, unchanged versus the Tradegate close of October 14, 2026.
Oramed Pharmaceuticals had a market capitalization of USD 173.5 million on October 15, 2026.

ORMP, US68403P2039, Illustration mit AI erstellt.

Oramed Pharmaceuticals has November 12, 2026 listed as its next quarterly reporting date, giving investors the next scheduled checkpoint for the biotechnology company. The date appears in the company profile on wallstreetONLINE. Oramed Pharmaceuticals stock was EUR 3.72 at Lang & Schwarz on October 15, 2026 at 8:47 p.m. CEST, unchanged versus the Tradegate close of October 14, 2026.

Valuation stays tied to earnings

The latest quote data put Oramed's market capitalization at USD 173.5 million and its P/E ratio at 1.01 on October 15, 2026. The company had 62,797 shares in volume against an average volume of 187,029 shares, a trading level that was 66.43 percent below the average.

On Nasdaq, the stock last traded at USD 4.17 on October 15, 2026 at 2:53 p.m. ET. That price stood 23.77 percent below the USD 5.47 52-week high and 99.52 percent above the USD 2.09 52-week low.

Price position in the yearly range

The euro quotation was steady against the Tradegate close, while the home-market quote remained inside its USD 2.09 to USD 5.47 52-week range. The gap to the high leaves a measurable distance between the current Nasdaq price and the year's peak.

Oramed's common stock is registered on The Nasdaq Capital Market and the Tel Aviv Stock Exchange, with the ticker ORMP, according to the company's September 15, 2026 filing with the SEC. The same filing said the annual meeting was held on September 15, 2026.

Comparison with peers

ORMP (Nasdaq, USD): unchanged, P/E 1.01, market capitalization USD 173.5 million

CollPlant Biotechnologies (Nasdaq, USD): minus 9.69 percent, P/E minus 0.40, market capitalization USD 4.8 million

Rani Therapeutics (Nasdaq, USD): plus 1.78 percent, P/E minus 2.54, market capitalization USD 44.6 million

Next date for the stock

The November 12 reporting date is the next calendar marker identified for Oramed Pharmaceuticals. The company profile also places the business in biotechnology, where earnings can be heavily influenced by investment results and development spending rather than recurring product sales.

Tradegate price holds steady

For German investors, the euro quote remained at EUR 3.72 at Lang & Schwarz on October 15, 2026 at 8:47 p.m. CEST, unchanged versus the Tradegate close of October 14, 2026.

The further course of trading is shown by the continuously updated real-time quote of Oramed Pharmaceuticals stock.